Repros Therapeutics Inc. Allowed To Conduct Phase 1 And 2 Clinical Studies Of Low Dose Oral Proellex® In The Treatment Of Uterine Fibroids And Endometriosis

THE WOODLANDS, Texas, March 17, 2014 (GLOBE NEWSWIRE) -- Repros Therapeutics Inc.® (Nasdaq:RPRX) today reported it has received guidance from the FDA indicating that Repros may proceed to conduct Phase 1 and 2 studies of oral Proellex® under two separate INDs for endometriosis and uterine fibroids, while remaining on partial clinical hold. The FDA guidance provides that the highest allowed dose will be 12 mg daily. Repros is currently conducting a Phase 2 study for the use of Proellex in severe endometriosis and plans to submit a Phase 2 protocol for the treatment of symptomatic fibroids.

Help employers find you! Check out all the jobs and post your resume.